Glioblastoma and Colon Cancer research from ASCO 2010 conference

The most interesting and noteworthy glioblastoma and colon cancer research from the ASCO 2010 conference (June 4-8 in Chicago).

Click the links for more information on the ASCO website.

Novel Technique Shows Promise for Treatment of Recurrent Glioblastoma

A noninvasive treatment showed promising results in comparison with standard chemotherapy regimens in patients with recurrent glioblastoma, according to a presentation at Saturday’s Oral Abstract Session: Central Nervous System Tumors. In the treatment, called NovoTTF, low-intensity alternating electric fields are applied to the patient’s scalp, said Roger Stupp, MD, of the University of Lausanne Hospital, Switzerland (Abstract LBA2007).

mFOLFOX6 plus Cetuximab Confers No Benefit for Stage III Resected Colon Cancer

Surprising results from a phase III trial of patients with stage III colorectal cancer showed no disease-free survival (DFS) benefit when cetuximab is added to adjuvant chemotherapy with mFOLFOX6 after surgery. These findings stand in contrast to the positive benefits observed in earlier trials of FOLFOX plus cetuximab in patients with metastatic colon cancer, suggesting that stage III and stage IV colon cancer may be mechanistically different diseases. Notably, this lack of benefit was observed in patients with wild-type (WT) and mutant KRAS status.

Stay in the Know

Subscribe to the Navigating Cancer blog for the latest news, innovations, and best practices in oncology care.